TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03756090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
Study: NCT03931655

Intervention type: DIAGNOSTIC_TEST
Intervention: Spectroscopic photoacoustic imaging
Description: Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
Study: NCT03964571

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WOUNDCHEK
Description: fluid swab of wound and measurement of wound onto film
Study: NCT02257255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pfannenstiel cesarean section
Description: Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misgav-Ladach cesarean section
Description: Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
Study: NCT02384005

Intervention type: OTHER
Group type: OTHER
Intervention: Self-anal exam arm
Description: After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
Study: NCT02865057

Intervention type: PROCEDURE
Intervention: Vaginal assessment
Description: Vaginal assessment of position prior to delivery

Intervention type: PROCEDURE
Intervention: Vaginal assessment
Description: Vaginal assessment of position prior to delivery
Study: NCT00283387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
Study: NCT04608188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer Camp
Description: The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
Study: NCT00055237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
Study: NCT04355273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study: NCT00283387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betaine
Description: Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.
Study: NCT04567082

Intervention type: DIAGNOSTIC_TEST
Intervention: Examination of saliva
Description: Collection of saliva samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Examination of saliva
Description: Collection of saliva samples
Study: NCT00030186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 60mg
Description: 60mg orally 2 times a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cep-701 80mg
Description: 80mg 2 times a day, dependent upon response to cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cep-701 40mg
Description: 40mg 2 times a day, dependent upon response to cycle 1
Study: NCT00283387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.
Study: NCT03268629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Joyful Sleep
Description: The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
Study: NCT04665596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Description: Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
Study: NCT04355273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study: NCT01829048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q12h
Study: NCT00102635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR)
Description: Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH66336
Description: Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
Study: NCT00565786

Intervention type: DEVICE
Intervention: ArCom® Polyethylene
Description: Argon packaged compression molded polyethylene

Intervention type: DEVICE
Intervention: ArComXL® Polyethylene
Description: Highly crosslinked Ultra High Molecular Weight Polyethylene
Study: NCT04454502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral colostrum administration
Description: In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
Study: NCT02630654

Intervention type: OTHER
Intervention: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
Study: NCT01417663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alt-711
Description: Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
Study: NCT00977418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART- Strategic Memory and Reasoning Training
Description: Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
Study: NCT01417663

Intervention type: DRUG
Group type: OTHER
Intervention: Alt-711
Description: Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical exercise training
Description: Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical exercise training
Description: Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
Study: NCT04656353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
Study: NCT01666977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15mg/kg
Study: NCT06407063

Intervention type: PROCEDURE
Intervention: Micro-decompression alone
Description: In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion
Study: NCT03823924

Intervention type: PROCEDURE
Intervention: Bone mineral density (BMD)
Description: The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body).

Intervention type: PROCEDURE
Intervention: Bone mineral density (BMD)
Description: The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body).
Study: NCT03435835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control/Sham Treatment
Description: Water at 33ºC was circulated through water-circulating trousers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control/Sham Treatment
Description: Water at 33ºC was circulated through water-circulating trousers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Therapy (HT)
Description: Water at 42-43ºC was circulated through the water-circulating trousers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Therapy (HT)
Description: Water at 42-43ºC was circulated through the water-circulating trousers.
Study: NCT04110236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE
Description: PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
Study: NCT06407063

Intervention type: PROCEDURE
Intervention: Decompression and instrumented fusion
Description: In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage
Study: NCT01666977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 30 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2
Study: NCT04110236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Discipline Module
Description: The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
Study: NCT03807180

Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi (exercise)
Description: Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
Study: NCT04306068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric protocol
Description: Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets.
Study: NCT01218867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-VEGFR2 CAR CD8 plus PBL
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Study: NCT01666977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2
Study: NCT01218867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-VEGFR2 CAR CD8 plus PBL
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-VEGFR2 CAR CD8 plus PBL
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Study: NCT03628157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss® bovine bone alone
Description: Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geistlich Bio-Oss® bovine bone alone
Description: Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
Study: NCT00892437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: Cobicistat (COBI) 150 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI placebo
Description: Placebo to match COBI administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV placebo
Description: Placebo to match RTV administered orally once daily
Study: NCT00448461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: comparison between heparin and bivalirudin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalirudin
Description: comparison between heparin and bivalirudin
Study: NCT01033994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS902330
Description: 10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AS902330
Description: 10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Study: NCT03705390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB
Description: Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks